Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4291 - Combined analysis of gene expression profiles in 2 preoperative trials with afatinib and cetuximab in head and neck squamous cell carcinoma

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Paolo Bossi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

P. Bossi1, S. Schmitz2, J. Machiels3, L.F. Licitra1, C. Fortpied Lefevre4, C. Caballero5, S. Canevari6, L. De Cecco6

Author affiliations

  • 1 Head And Neck Medical Oncology Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2 Department Of Head And Neck Surgery, Cliniques Universitaires St. Luc, 1200 - Brussels/BE
  • 3 Oncology, Cliniques Universitaires St. Luc, 1200 - Brussels/BE
  • 4 Statistical, EORTC, 1200 - Brussels/BE
  • 5 Head And Neck Group, EORTC, 1200 - Brussels/BE
  • 6 Functional Genomics And Bioinformatics, Department Of Applied Research And Technology Development, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
More

Resources

Abstract 4291

Background

Only a minority of head and neck squamous cell carcinoma (HNSCC) patients (pts) respond to targeted agents acting on epidermal growth factor pathway. We investigated the changes of gene expression profiles in 2 preoperative window of opportunity trials, to allow a further investigation in mechanisms of response.

Methods

Thirty and 20 pts with similar characteristics were treated for 2 weeks before surgery with afatinib (EORTC 90111-24111 NOCI HNCG trial, Ann Oncology 2017) and cetuximab (Schmitz S, Ann Oncology 2013), respectively. The gene expression profile obtained by microarray platform was compared by a paired analysis pre and post treatment. Gene sets were defined according to GSEA and only sets with q-value FDR < 0.05 differences were considered. Clinical response was analysed according to primary endpoint of the trials (FDG-PET response).

Results

Pre- and post-targeted treatment paired histological samples from 20 and 15 pts were evaluable for gene expression, from afatinib and cetuximab series, respectively. The following gene sets were commonly downregulated by the treatment: G2M checkpoint, MYC and E2F targets and MTORC. On the opposite, the gene sets which resulted upregulated were: angiogenesis, epithelial-mesenchymal transition, inflammatory response and NOTCH signalling. A substantial overlapping of molecular alteration between the 2 series has been observed, thus allowing a further meta-analysis combining the 2 datasets to analyse profiles associated to response. Preliminary data in afatinib series showed a strong downregulation of hypoxia gene signature only in responding pts.

Conclusions

In 2 independent studies with afatinib and cetuximab in window of opportunity setting, we observed similar molecular alterations induced by the drugs. Further insights in the pathways involved in response to both drugs are ongoing.

Clinical trial identification

Legal entity responsible for the study

Paolo Bossi.

Funding

AIRC and Italian Ministry of Health.

Editorial Acknowledgement

Disclosure

P. Bossi: Advisory Board: Merck Serono. J.-P. Machiels: Advisory board: Boerhingher-Ingelheim. L.F. Licitra: Advisory board and research supports: Merck Serono, Boehringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.